Aruna Hari Sharma on Phillips C10 TEM in University of Miami Dietrich #39;s Lab Nov 13, 2012.mov
Aruna Hari Sharma from Uppsala University were invited to work on Transmission Electron Microscopy on Grids pertaining to the brain and spinal cord injury under various protocols in University of Miami, FL, USA. Dalton Dietrich, Director of the Institute Miami Project to Cure Paralysis and Helen Bramlett have great interest in CNS injury and neuroregeneration. Since they are good friends of Aruna Hari Sharma since 80 #39;s they are now working together on various aspects of CNS injury. In this video Aruna is seen doing TEM on grids from injured brains. Hari is also seen in helping Aruna to achieve the target.From:Hari SharmaViews:0 0ratingsTime:02:15More inScience Technology

Continue reading here:
Aruna

Recommendation and review posted by sam

Spasms 3 1/2 yrs
Spinal cord injury leg spasms from touch 3 1/2 yrs postFrom:britbrit317Views:8 0ratingsTime:01:02More inPeople Blogs

Read the original here:
Spasms 3 1/2 yrs - Video

Recommendation and review posted by sam

Pulkit Gupta Taking first steps after spinal cord injury. Sharing the Happy Moments by Prodyut Das
Pulkit Gupta suffered road traffic accident due to which he got complete spinal cord injury #D4-5, # tibia bone head injury. After taking intense training and exercises, this is his first walk. http://www.physiotherapy-treatment.comFrom:Prodyut DasViews:0 0ratingsTime:00:31More inEducation

Continue reading here:
Pulkit Gupta Taking first steps after spinal cord injury. Sharing the Happy Moments by Prodyut Das - Video

Recommendation and review posted by sam

Egan Wellness Anti Aging Skin Care Spa Video | Spa in Covington
my.datasphere.com Egan Wellness Skin Care Spa! The best in primary care, preventative medicine and aesthetic services! Pamela Egan, Nurse Practitioner has completed a Fellowship with the American Academy of Anti-Aging Regenerative Medicine. We are focused on providing high-quality service and customer satisfaction - we will do everything we can to meet your expectations. Our company is based on the belief that our customers #39; needs are of the utmost importance. Our entire team is committed to meeting those needs. As a result, a high percentage of our business is from repeat clients and referrals. Look Good Feel good with Evidenced-based conventional and natural methods including "Natural Hormone Replacement, Metabolic, and Nutritional Medicine" for men women. We also offer a full complement of skin treatments including Venus Freeze, designer facials, chemical peels, Botox Fillers. Whether you #39;re looking to obtain optimum health or to pamper yourself, the professionals at Egan Wellness Skin Care Spa are eager to meet all of your needs. Give us a call at (985) 892-3031 to schedule your appointment or visit us at http://www.pamelaegan.com to learn more about the services we offer. 12545376 Facials, Microdermabrasion, LED Light Therapy, Lipolysis, Collagen and Elastic Restructuring, Syneron Auroro IPL, Prestige Peel (Mid Depth), Brilliance Peel, Venus Freeze, Covington, WWLFrom:DataSphereVideosViews:1 1ratingsTime:01:17More inPeople Blogs

Read the original:
Egan Wellness Anti Aging

Recommendation and review posted by sam

Making It Cool: Gen Z Meets Manufacturing
Aspiring roboticists are seeking to change the way we live, work, play and fight wars through artificial intelligence; 3D printing has taken college classrooms by storm allowing art students to create mold models once reserved for technical professionals, and students in institutes of regenerative medicine are actually manufacturing organs for humans and animals. So what makes manufacturing cool? How do we get today #39;s youth excited about new opportunities in manufacturing? Listen to our live broadcast as our panelists talk about making manufacturing cool. Panelists: Chris Anderson, Editor of Wired Magazine and CEO of 3D Robotics Adam Friedman, Director of the Pratt Center for Community Development Aly Khalifa, President at Gamil Design, Inc. Joe LaRussa, Director of Membership at Society of Manufacturing Engineers AJ Sweatt, Principal at AJ Sweatt Logic CommunicationsFrom:Anita Brown-GrahamViews:0 0ratingsTime:59:34More inNews Politics

See more here:
Making It Cool: Gen Z Meets Manufacturing - Video

Recommendation and review posted by sam

Tissue Engineering And Regenerative Medicine: Advancing Toward Clinical Therapies : Chapter 1 From T
ll4.me Tissue Engineering And Regenerative Medicine: Advancing Toward Clinical Therapies : Chapter 1 From Transitional Approaches In Tissue Engineering Reg Chapter 1 from Translational Approaches in Tissue Engineering and Regenerative Medicine,Jeremy J. Mao, Gordana Vunjak-Novakovic, Antonios G. Mikos, Anthony Atala, Editors Publisher: Artech House Publishers Illustration: N Language: ENG Title: Tissue Engineering and Regenerative Medicine: Advancing Toward Clinical Therapies : Chapter 1 from Transitional Approaches in Tissue Engineering Reg Pages: 00000 (Encrypted PDF) On Sale: 2007-11-30 SKU-13/ISBN: 9781607832362 Category: Technology Engineering : General Chapter 1 from Translational Approaches in Tissue Engineering and Regenerative Medicine,Jeremy J. Mao, Gordana Vunjak-Novakovic, Antonios G. Mikos, Anthony Atala, Editors Publisher: Artech House Publ technology, engineering, generalFrom:shirleymiller364Views:0 0ratingsTime:00:14More inPeople Blogs

Read the original post:
Tissue Engineering And Regenerative Medicine: Advancing Toward Clinical Therapies : Chapter 1 From T - Video

Recommendation and review posted by sam

Jill Helms, "Forever Young: The New Frontier of Stem Cell Medicine"
The good part about getting older is that we gain some wisdom and patience. The bad part is that our bodies start to wear out. But what if we could revitalize our damaged bits back to a healthy state? Come hear what the field of Regenerative Medicine is striving to achieve, and learn how it all begins with the stem cell. Jill Helms is a professor in Plastic and Reconstructive Surgery in the department of surgery at Stanford University #39;s School of Medicine. This Classes Without Quizzes lecture was filmed on location at Stanford Reunion Homecoming 2012 by the Stanford Alumni Association.From:StanfordAlumniViews:11 0ratingsTime:54:05More inEducation

Excerpt from:
Jill Helms, "Forever Young: The New Frontier of Stem Cell Medicine" - Video

Recommendation and review posted by sam

ANAHEIM, Calif., Nov. 13, 2012 /PRNewswire/ --A step ahead of the colossal skincare market, Ageless Derma, an innovative, anti-aging skincare company, leads its competition as the first to integrate the latest technology, PhytoCellTec. This cutting-edge technology cultivates stem cells from a rare apple and when incorporated into the Ageless Derma Stem Cell and Peptide Anti-Wrinkle cream, has proven to diminish wrinkles with exceptional results.

Patent pending, PhytoCellTec Malus Domestica is a liposomal preparation of apple stem cells designed to protect skin stem cells. Known for minimal shriveling and extended longevity, the Uttwiler Spalauber apple is rich in proteins, phytonutrients, and long-living cells. PhytoCellTec Malus Domestica is a scientifically proven breakthrough that effectively combats skin aging.

"We were excited to find new, revolutionary stem cell technology," said Dr. Farid Mostamand, owner and founder of the Ageless Derma skincare line. "This extraordinary process is a leap forward. Our customers want non-surgical options to fight wrinkles and sagging skin and PhytoCellTec technology provides exactly that. This has produced remarkable results for eliminating wrinkles so we integrated it into our Ageless Derma anti-wrinkle cream."

Pioneered by Mibelle BioChemistry Group, the founding company hosts scientific studies to substantiate claims that PhytoCellTec Malus Domestica provides revolutionary skin rejuvenation. Honored with the BSB Innovation Award in 2008 for best ingredient, Mibelle BioChemistry Group developed PhytoCellTec technology to enable plant stem cells to grow in considerable numbers. In comprehensive studies the company was able to prove PhytoCellTecMalus Domestica, the dynamic ingredient derived from the apple stem cells, supports longevity and vitality of skin stem cells.

In a study of volunteers ranging in age from 37 to 64, 100% of the subjects showed significant decreases in wrinkle depth. The volunteers applied a concentration of 2% PhytoCellTec Malus Domestica twice daily for 28 days to "crow's feet," or wrinkles near the eyes, to diminish wrinkles.

PhytoCellTec enables the cultivation of stem cells by using the same repair methods plant cells use. The PhytoCellTec process selects a diminutive piece of plant material which is then damaged to result in callus formation. The formations are incubated and harvested in order to obtain stem cells.

"Along with this miraculous stem cell factor, our anti-aging creams have other effective, safe ingredients such as vitamins, minerals, and peptides. Peptides also play a big role in our anti-wrinkle creams as they stimulate collagen growth to keep skin looking young," said Dr. Mostamand.

About Ageless Derma:

Ageless Derma is accredited with the Better Business Bureau and offers a 30-day money-back guarantee. Ageless Derma products are available at Focus Medical Spa in Anaheim, CA, through the website http://www.agelessderma.com, or toll-free (877) 777-1940. For more information on Ageless Derma, please contact Dr. Farid Mostamand at mostamand5@gmail.com or call (877) 777-1940.

Contact

Continued here:
Ageless Derma Formulates Apple Stem Cells into Anti-Wrinkle Cream with PhytoCellTec Technology

Recommendation and review posted by Bethany Smith

What Are Stem Cells | Stem Cell Malaysia
stemcellmalaysia.com Stem cells are non-differentiated cells with the ability to divide and produce any body cell types. The ability of stem cells to differentiate and self-regenerate impart great possibilities for disease treatment other than for restoring health, beauty and anti-aging. Clinically proven for certain illness and conditions, stem cells can now be introduced into the body to repair and replace damaged organ or tissue. For more informative articles on stem cells and stem cell therapy, please visit Stem Cell Malaysia at http:/stemcellmalaysia.com/.From:stemcells2012Views:2 1ratingsTime:06:29More inHowto Style

See more here:
What Are Stem Cells | Stem Cell Malaysia - Video

Recommendation and review posted by Bethany Smith

My Hair Care Routine Favorite Products
Below are all the items mentioned in the video: Ovation Cell Therapy System (they have the holiday set an use the code survey2012) Organix coconut milk Loreal evercream TRESemme Thermal heat tamer Macadamia Healing Oil TRESemme 4+4 Styling glaze Paul Mitchel firm style dry wax Sexy hair play dirty textureizing hairspray/wax Hair Doughnut from Clairs or Sallys Wide tooth comb Teasing comb/brush (sallys) Revlon Hot air hair styler Like Subscribe 🙂 Don #39;t forget to follow me on Instagram Twitter @The1nonlymaria and now I have my blog.From:The1nonlymariaViews:1 1ratingsTime:19:29More inHowto Style

Read this article:
My Hair Care Routine

Recommendation and review posted by Bethany Smith

LITCHFIELDWith a name inspired by a Celtic goddess who could manifest magic for the good of others, an Elkhound mix that suffered the depths of animal abusenearly to the point of deathis benefiting from cutting-edge veterinary medicine at a practice in Bantam.

Rhiannon, whose name derives from the Stevie Nicks song about the legendary goddess, is one of two patients helping to make veterinary history in Connecticut through the states first in-clinic stem cell regenerative therapy treatments.

Such loving care stands in stark contrast to the condition Rhiannons owner, Edward Milne of Cheshire, found the 14-year-old in the first time he saw her.

I found her hanging by her neck from a tree as I was driving along a back country road in Northford, CT when she was about two years old, Mr. Milne wrote in an e-mail to the Bantam clinic, Animal Health Practice Inc.

When I confronted the owner, Mr. Milne wrote, he admitted that he had not fed her or provided her with water for some time, and when she didnt die, he hung her from the tree to finish her off. I guess it was fate that brought us together.

Another type of Rhiannon-esque fate brought the dog to a vet who is performing a ground-breaking procedure to treat severe arthritis in her elbow and back.

Rhiannon is the first dog to receive MediVet Americas non-controversial adipose regenerative stem cell therapy, according to a release sent by the company. MediVet is a global leader in veterinary science located in 29 countries. The company develops advanced cellular treatments and natural herbal remedies designed to maximize animal performance, repair, recovery and general wellness.

Were very excited to be the first veterinarians in Connecticut to offer this new technology, said Dr. Angela Erickson-Greco Monday morning.

In addition to Rhiannon, Dr. Erickson-Greco is also administering the treatment to Dakota, a Bernese Mountain Dog and Great White Pyrenees mix, who has bilateral ACL tears, which means she has torn a crucial ligament in both of her knees.

New Milford resident Cathy Morsey said Dakota had a limp in her front leg in the shoulder area at 6 months old. In January of last year, we had a wet snow and she slid on the snow and tore a cartilage in her knee, said Ms. Morsey. Continued...

Follow this link:
Rhiannon, an Abused Dog, and Dakota, Get Stem Cell Therapy in Litchfield

Recommendation and review posted by Bethany Smith

NEW YORK, Nov. 13, 2012 (GLOBE NEWSWIRE) -- NeoStem, Inc. (NBS) ("NeoStem" or the "Company"), an emerging market leader in the fast growing cell therapy industry, today announced that the Company has completed the divestiture of its 51% ownership interest in Suzhou Erye Pharmaceutical Co. Ltd. ("Erye"), a China-based generic pharmaceutical company. The divestiture provides NeoStem with $12,280,000 in cash and removes from the Company's balance sheet over $30 million in short and long-term debt obligations. Erye also returns 1,040,000 shares representing approximately 0.7% of the Company's outstanding common stock, 1,170,000 stock options representing approximately 5.1% of the Company's outstanding options and 640,000 warrants to purchase common stock held by Erye representing approximately 1.1% of the Company's outstanding warrants.

"We are very pleased to have reached this significant milestone in our business," said Dr. Robin Smith, Chairman and CEO of NeoStem. "The Erye divestiture brings non-dilutive capital that bolsters our cash position in the United States, reduces legal and financial reporting expenditures, simplifies our financial statements and focuses our efforts exclusively on the rapidly growing cell therapy industry. The divestiture also paves the way for the Company to qualify for new funding through the National Institutes of Health (NIH) Small Business Innovation Research (SBIR) program which would support our pre-clinical development of VSELTM Technology. NeoStem will also be able to invest more resources into its cell therapy development and contract manufacturing activities."

About NeoStem, Inc.

NeoStem, Inc. continues to develop and build on its core capabilities in cell therapy, capitalizing on the paradigm shift that we see occurring in medicine. In particular, we anticipate that cell therapy will have a significant role in the fight against chronic disease and in lessening the economic burden that these diseases pose to modern society. We are emerging as a technology and market leading company in this fast developing cell therapy industry. Our multi-faceted business strategy combines a state-of-the-art contract development and manufacturing subsidiary, Progenitor Cell Therapy, LLC ("PCT"), with a medically important cell therapy product development program, enabling near and long-term revenue growth opportunities. We believe this expertise and existing research capabilities and collaborations will enable us to achieve our mission of becoming a premier cell therapy company.

Our contract development and manufacturing service business supports the development of proprietary cell therapy products. NeoStem's most clinically advanced therapeutic product candidate, AMR-001, is being developed at Amorcyte, LLC ("Amorcyte"), which we acquired in October 2011. Amorcyte is developing a cell therapy for the treatment of cardiovascular disease and is enrolling patients in a Phase 2 trial to investigate AMR-001's efficacy in preserving heart function after a heart attack. Athelos Corporation ("Athelos"), which is approximately 80%-owned by our subsidiary, PCT, is collaborating with Becton-Dickinson in the early clinical exploration of a T-cell therapy for autoimmune conditions. In addition, pre-clinical assets include our VSEL TM Technology platform as well as our mesenchymal stem cell product candidate for regenerative medicine. Our service business and pipeline of proprietary cell therapy products work in concert, giving us a competitive advantage that we believe is unique to the biotechnology and pharmaceutical industries. Supported by an experienced scientific and business management team and a substantial intellectual property estate, we believe we are well positioned to succeed.

For more information on NeoStem, please visit http://www.neostem.com.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements reflect management's current expectations, as of the date of this press release, and involve certain risks and uncertainties. Forward-looking statements include statements herein with respect to the successful execution of the Company's business strategy, including with respect to the Company's or its partners' successful development of AMR-001 and other cell therapeutics, the size of the market for such products, its competitive position in such markets, the Company's ability to successfully penetrate such markets and the market for its contract development and manufacturing ("CDMO") business, and the efficacy of protection from its patent portfolio, as well as the future of the cell therapeutics industry in general, including the rate at which such industry may grow. The Company's actual results could differ materially from those anticipated in these forward- looking statements as a result of various factors, including but not limited to matters described under the "Risk Factors" in the Company's Annual Report on Form 10-K filed with the Securities and Exchange Commission on March 20, 2012 and in the Company's other periodic filings with the Securities and Exchange Commission, all of which are available on its website. The Company does not undertake to update its forward-looking statements. The Company's further development is highly dependent on future medical and research developments and market acceptance, which is outside its control.

Excerpt from:
NeoStem Closes Divestiture of Its Ownership Interest in Suzhou Erye

Recommendation and review posted by Bethany Smith

THE WOODLANDS, Texas--(BUSINESS WIRE)--

Opexa Therapeutics, Inc. (OPXA), a company developing Tcelna, a novel T-cell therapy for multiple sclerosis (MS), today announced that Health Canada has approved the Company's Clinical Trial Application (CTA). The application was filed with the Biologics and Genetic Therapies Directorate. With this approval by the Canadian Health Authority, Opexa expects to expand its ongoing clinical trial in Secondary Progressive MS (SPMS) patients to include several sites in Canada. The Abili-T trial, a Phase 2b study of Tcelna in subjects with SPMS, is currently enrolling patients in the United States.

To date, over a half of the clinical sites have been initiated and approximately ten percent of subjects have been enrolled. Enthusiasm and support remains strong among the patients and the treatment sites. The trial is expected to enroll 180 patients in approximately 30 sites in the U.S. and Canada and conclude in 2015.

In addition, at the end of September, The United States Adopted Names Council (USANC) officially adopted Tcelnas non-proprietary name, imilecleucel-T. USANC is tri-sponsored by the American Medical Association, the United States Pharmacopeial Convention, and the American Pharmacists Association. USANC aims to standardize drug nomenclature by selecting informative and unique non-proprietary names for all pharmaceuticals marketed in the U.S. The name imilecleucel-T is derived from a set of regulations and guidelines set forth by USANC specific to cellular therapies. The non-proprietary name will be used in conjunction with the brand name, Tcelna, in publications and certain communication material appearing as Tcelna (imilecleucel-T).

We are very pleased with the progress of the Abili-T SPMS clinical trial to date, stated Neil K. Warma, President and CEO of Opexa. The clinical trial sites are being activated as planned and screening of patients for enrollment into the trial is on schedule due to the patients enthusiasm to participate in the trial and the efficient cooperation among the sites, our clinical staff and the various vendors. SPMS represents a market in dire need of new, safe and effective therapies. Currently there is only one FDA-approved treatment in the U.S. and it carries a safety warning that significantly limits its use. With the approval of the regulatory package by the Canadian Health Authority, we have taken another key step in the progress of the Abili-T trial, as it enables us to access large clinical practices that should enhance patient enrollment. Additionally, USANCs acceptance of Tcelnas non-proprietary name supports our rebranding effort and enables us to have more flexibility in meeting submission criteria in certain publications. We are also continuing to focus on securing the necessary capital required to continue and complete the trial, added Mr. Warma.

About SPMS

SPMS is a progressive phase of MS which is characterized by a steady progression of clinical neurological damage with or without relapses. After ten years of disease characterized by relapse events and remitting disability (RRMS), approximately 50 percent of patients will have progressed to SPMS. In SPMS, relapses dissipate over time and subjects experience general progression and increasing disability. It is believed that the resulting neurological damage cannot be reversed.

About Tcelna

Tcelna (imilecleucel-T) is a personalized therapy that is specifically tailored to each patient's disease profile. Tcelna is manufactured using ImmPath, Opexa's proprietary method for the production of a patient-specific T-cell immunotherapy, which encompasses the collection of blood from the MS patient, isolation of peripheral blood mononuclear cells, generation of an autologous pool of myelin-reactive T-cells (MRTCs) raised against selected peptides from myelin basic protein (MBP), myelin oligodendrocyte glycoprotein (MOG) and proteolipid protein (PLP), and the return of these expanded, irradiated T-cells back to the patient. These attenuated T-cells are reintroduced into the patient via subcutaneous injection to trigger a therapeutic immune system response. Opexa believes the potential combination of efficacy, superior safety, excellent tolerability and administration may position Tcelna as an MS treatment of choice as compared to existing therapeutics.

About Opexa

See the rest here:
Opexa Receives Clinical Trial Approval From Health Canada for Novel T-Cell Therapy

Recommendation and review posted by Bethany Smith

SAN DIEGO--(BUSINESS WIRE)--

Cytori Therapeutics (CYTX) announced this morning that a peer-reviewed case series using Cytoris cell therapy to treat patients suffering from complex cryptoglandular fistula has been published in the current issue of the British Medical Journal: Case Reports. The patients were treated by Dr. David Borowski and Dr. Pud Bhaskar, Consultant Surgeons at the University Hospital of North Tees, a National Health Service (NHS) hospital in the United Kingdom.

In this case series, three patients suffering from long-standing complex cryptoglandular fistula-in-ano were treated using fat grafts enriched with their own adipose-derived stem and regenerative cells (ADRCs), processed using Cytoris Celution system. The ADRC-enriched graft was injected directly into the tissue surrounding the fistula to close the fistula track. The interior opening of the fistula was closed with a mucosal advancement flap. All three patients remain fully healed at two to three year follow-up, with one patient undergoing colostomy reversal to restore bowel continuity.

These three patients are the initial cases treated within a phase I feasibility study; all three had been suffering from the symptoms of their fistulae with considerable reduction in their ability to lead a normal life, said Dr. Borowski. Other treatments had failed, and the successful treatment with ADRC-enriched lipofilling has helped them to resume a normal lifestyle. With these encouraging results, we are currently collaborating with several other centers in the UK and Europe to explore the efficacy of this treatment in a greater number of patients, and for other indications, in the setting of clinical trials.

This successful case series at a respected NHS hospital in the UK illustrates the breadth of Cytoris soft tissue business and the potential of Cytoris cell therapy to help patients who have few, if any, alternative treatment options. The data, showing that ADRC-enriched fat grafting appears to be safe and feasible for cryptoglandular fistula patients, validates the expansion of Cytoris CE Mark claims to include cryptoglandular fistula and other soft tissue and wound indications in August of this year.

Based on a report of the American College of Surgeons, there are between 43,000 and 140,000 fistula cases per year in Europe, of which cryptoglandular fistula are a subset. Cryptoglandular fistula is the most common cause of persistent perianal infection, causing abnormal fecal contamination and potentially incontinence.

About Cytori

Cytori Therapeutics, Inc. is developing cell therapies based on autologous adipose-derived regenerative cells (ADRCs) to treat cardiovascular disease and repair soft tissue defects. Our scientific data suggest ADRCs improve blood flow, moderate the immune response and keep tissue at risk of dying alive. As a result, we believe these cells can be applied across multiple ischemic conditions. These therapies are made available to the physician and patient at the point-of-care by Cytoris proprietary technologies and products, including the Celution system product family. http://www.cytori.com

Cautionary Statement Regarding Forward-Looking Statements

This communication includes forward-looking statements regarding events, trends and business prospects, which may affect our future operating results and financial position. Such statements, including, but not limited to, those regarding the potential of Cytoris cell therapy to help no-option patients, and statements regarding the safety and feasibility of this procedure for cryptoglandular fistula patients, are subject to risks and uncertainties that could cause our actual results and financial position to differ materially. Some of these risks and uncertainties include the uncertainties regarding the collection and results of clinical data, as well as our history of operating losses, regulatory uncertainties, dependence on third party performance, and other risks and uncertainties described under the "Risk Factors" section in Cytori's Securities and Exchange Commission Filings on Form 10-K and Form 10-Q. Cytori assumes no responsibility to update or revise any forward-looking statements contained in this press release to reflect events, trends or circumstances after the date of this press release.

Read this article:
Cryptoglandular Fistula Repair Case Series Using Cytori Cell Therapy Published in the British Medical Journal: Case ...

Recommendation and review posted by Bethany Smith

JERUSALEM--(BUSINESS WIRE)--

Gamida Cell Ltd., a world leader in stem cell population expansion technologies and stem cell therapy products for transplantation and regenerative medicine, announced today that the first patient, enrolled in its pilot study of NiCord as an investigational treatment for sickle cell disease (SCD), has been transplanted at Duke University in North Carolina.

Gamida Cell CEO Dr. Yael Margolin said, The NiCord study is a first step in broadening Gamida Cells pipeline of cell therapies to treat patients who suffer from severe non-malignant diseases with a very large unmet clinical need.

SCD is a group of inherited red blood cell disorders where red blood cells become hard and sticky and look like a C-shaped farm tool called a sickle. According to statistics, SCD affects 90,000 to 100,000 in the US alone, mainly African-Americans and Hispanic-Americans. Symptoms range in type and severity. SCD can be fatal and to date, the only cure for SCD is stem cell transplantation from a family related matched donor.

Dr. Margolin continued, Sickle cell disease can be cured with a successful bone marrow transplantation, especially from a family related fully matched donor. Most patients do not pursue this option, since they do not have the suitable donor. NiCord is intended to reverse this situation and provide a readily available cure.

NiCord is an expanded cell graft derived from an entire unit of umbilical cord blood and enriched with stem cells. NiCord was developed based on Gamida Cells proprietary NAM technology.

The official name of the study is Allogeneic Stem Cell Transplantation of NiCord, Umbilical Cord Blood-Derived Ex Vivo Expanded Stem and Progenitor Cells, in Combination With a Second, Unmanipulated Cord Blood Unit in Patients With Sickle Cell Disease. http://www.clinicaltrials.gov/ct2/show/NCT01590628?term=nicord&rank=1. A total of 10 patients, ages 2 21, will be enrolled in the NiCord study, a single center, single arm trial evaluating the safety and efficacy of transplanting NiCord together with a second un-manipulated cord blood unit in patients with SCD following myeloablative therapy. The study will also assess transplant-related mortality, event-free survival and overall survival at 100, 180 and 365 days, respectively.

About Gamida Cell

Gamida Cell is a world leader in stem cell population expansion technologies and stem cell therapy products for transplantation and regenerative medicine. The companys pipeline of stem cell therapy products are in development to treat a wide range of conditions including blood cancers, solid tumors, non-malignant hematological diseases such as hemoglobinopathies, neutropenia and acute radiation syndrome, autoimmune diseases and metabolic diseases as well as conditions that can be helped by regenerative medicine. Gamida Cells therapeutic candidates contain populations of adult stem cells, selected from non-controversial sources such as umbilical cord blood, bone marrow and peripheral blood, which are expanded in culture. Gamida Cells current shareholders include: Elbit Imaging (EMITF), Clal Biotechnology Industries (CBI.TA), Israel Healthcare Venture, Teva Pharmaceutical Industries (TEVA), Amgen, Denali Ventures and Auriga Ventures. For more information, please visit: http://www.gamida-cell.com.

Continue reading here:
First Pediatric Sickle Cell Disease Patient Receives NiCord® Stem Cell Transplantation in Gamida Cell Pilot Study at ...

Recommendation and review posted by Bethany Smith

For Immediate Release Sunday, November 11, 2012 1 p.m. EST

An international group of scientists has identified three genetic regions that predispose Asian women who have never smoked to lung cancer. The finding provides further evidence that risk of lung cancer among never-smokers, especially Asian women, may be associated with certain unique inherited genetic characteristics that distinguishes it from lung cancer in smokers.

Lung cancer in never-smokers is the seventh leading cause of cancer deaths worldwide, and the majority of lung cancers diagnosed historically among women in Eastern Asia have been in women who never smoked. The specific genetic variations found in this study had not been associated with lung cancer risk in other populations.

Although environmental factors, such as secondhand smoke (also known as environmental tobacco smoke) or exhaust from indoor cooking are likely account for some cases of lung cancer among Asian women who have never smoked, they explain only a small proportion of the disease. To gain a better understanding of lung cancer in Asian female never-smokers, researchers from the National Cancer Institute (NCI), part of the National Institutes of Health, partnered with researchers from several other countries to create the Female Lung Cancer Consortium in Asia to conduct one of the largest genome-wide association studies (GWAS) in female never-smokers to date. GWAS compares DNA markers across the genome between people with a disease or trait to people without the disease or trait.

"This study is the first large-scale genome-wide association study of lung cancer among never-smoking females anywhere in the world," said Qing Lan, M.D., Ph.D. , a senior investigator in NCIs Division of Cancer Epidemiology and Genetics, and the leader of the study.

The consortium, whose findings were reported Nov.11, 2012, online in Nature Genetics , conducted a GWAS that combined data from 14 studies that included a total of approximately 14,000 Asian women (6,600 with lung cancer and 7,500 without lung cancer). The studies included data on environmental factors, including exposure to secondhand smoke.

The consortium found that variations at three locations in the genome two on chromosome 6 and one on chromosome 10 were associated with lung cancer in Asian female never-smokers. The discovery on chromosome 10 was particularly significant because it has not been found in any other GWAS of lung cancer in white or Asian populations.

Our study provides strong evidence that common inherited genetic variants contribute to an increased risk of lung cancer among Asian women who have never smoked, said Nathaniel Rothman, M.D., a senior investigator in NCI's Division of Cancer Epidemiology and Genetics and coauthor of the study. "These variants may also increase lung cancer risk associated with environmental factors, such as environmental tobacco smoke."

The researchers did not detect an association with variations at a location on chromosome 15 that has been associated with lung cancer risk in many previous GWAS of lung cancer in smokers. The absence of this association provides further support for the suggestion that the genetic variation on chromosome 15 may be smoking-related.

The researchers found some evidence that Asian women with one of the newly identified genetic variants may be more susceptible to the effects of environmental tobacco smoke. However, the authors note that more research is needed to draw definitive conclusions from this observation.

Originally posted here:
Gene variations linked to lung cancer susceptibility in Asian women

Recommendation and review posted by Bethany Smith

By Randy Dotinga HealthDay Reporter

FRIDAY, Nov. 9 (HealthDay News) -- In middle-aged people, a link may exist between weakened memory and genetic traits associated with obesity, raising the possibility that extra pounds change how our brains work, a new study suggests.

Researchers found the link between genes and memory in whites but not in blacks.

The research "could be useful in identifying people who may need more help with declining cognition," said John Speakman, a professor at the Institute of Biological and Environmental Sciences at the University of Aberdeen in Scotland, who is familiar with the findings.

Although some people believe obesity is purely a failure of individual will, scientists think genetic makeup has a lot to do with the propensity to gain extra pounds. Studies of twins and families suggest that genes account for about 65 percent of variance in body weight, Speakman said.

The new study focuses on four genetic traits related to a gene that's thought to play a role in obesity. Researchers looked for signs of the traits among nearly 8,400 white and 2,100 black people aged 45 to 64.

They found signs of a link between problems being able to remember words and two of the genetic traits. The connection held up even after the researchers adjusted their results so they wouldn't be thrown off by factors like large or small numbers of people who were of certain ages, genders, levels of obesity and education levels.

What's going on? It's not clear. Speakman said it's possible that the gene may affect both weight and memory.

"On the other hand, they could be linked because of negative impacts of obesity on memory function, or vice versa," he said. "The data don't allow us to see if that might be the case."

Dr. Michael Schwartz, director of the Diabetes and Obesity Center of Excellence at the University of Washington, in Seattle, pointed out that the connection held up even when the researchers tried to remove any influence of weight levels.

Continued here:
Study Ties Obesity-Related Gene to Weaker Memory

Recommendation and review posted by Bethany Smith

While I was at Spencer Wells poster at ASHG I was primarily curious about bar plots. Hes got really good spatial coverage, so Im moderately excited about the paper (though I didnt see much explicit testing of phylogenetic hypotheses, which I think this sort of paper has to do now; were beyond PCA and bar plots only papers). That being said, Spencer was more interested in me promoting the Scientific Grants Program. Heres some more information:

The Genographic Projects Scientific Grants Program awards grants on a rolling basis for projects that focus on studying the history of the human species utilizing innovative anthropological genetic tools. The variety of projects supported by the scientific grants will aim to construct our ancient migratory and demographic history while developing a better understanding of the phylogeographic structure of world populations. Sample research topics could include subjects like the origin and spread of the Indo-European languages, genetic insights into Papua New Guineas high linguistic diversity, the number and routes of migrations out of Africa, the origin of the Inca, or the genetic impact of the spread of maize agriculture in the Americas.

Recipients will typically be population geneticists, students, linguists, and other researchers or scientists interested in pursuing questions relevant to the Genographic Projects broad goal of exploring our migratory history. Recipients of Genographic scientific grant funds will become members of the Genographic Consortium, and will be expected to act as agents of the greater Genographic mission, participating in and reporting on multiple aspects of Genographic fieldwork, in addition to their own proposed and missionaligned pilot projects. Openness and transparency within the Consortium are the key values of the projects research team, and grantees will be expected to abide by this code of conduct.

If you poke through their material they say that the grant will be $25 to $50 thousand dollars. Thats 125 to 250 Geno 2.0 chips. Speaking of which, I sent in a chip about a month ago now. The results should be back soon.

So why was Spencer so keen on me pushing this again? (Ive mentioned it before) After being at ASHG 2012 Im shocked in the small sample space of people interested in these sorts of historical genetic questions. I say this because Ive reviewed/read most of the papers which were present as posters. I wonder on occasion if Im missing out on something, but these results indicate no, theres only so many labs doing this sort of work. The last is the key question. This is where bottom up non-academic science can do wonders. An Indian group presented a poster at ASHG, and when they told me of the similarities between Iyers and Bengali Brahmins I couldnt help but admit that Yes, I know that already, my friend Zack Ajmal came to that conclusion. If you are an academic you need to go beyond tools and methods and analytic insights which someone with a spare computer and some marginal free time can generate. Academic monopolies on these data are going to be short-lived at best. And all for the good. Im sick & tired of intellectual rents.

Excerpt from:
The Genographic Project’s Scientific Grants Program | Gene Expression

Recommendation and review posted by Bethany Smith

Hemis.fr / SuperStock

An article by SciDev.Net.

The international collection of the South Pacific's coconut palm species, held at a field gene bank in Papua New Guinea (PNG), is under threat from a disease outbreak close to the gene bank.

The warning came at a meeting on the Pacific coconut research and development (R&D) strategy in Samoa last week (31 October1 November), convened by the Australian Centre for International Agricultural Research and the Secretariat of the Pacific Community.

The deadly disease, Bogia Coconut Syndrome, is threatening the survival of a gene bank of region's most important tree, the coconut, a number of which are endemic. Named after the town of Bogia on the north coast of mainland PNG, the disease appears to be caused by bacteria similar to, but distinct from, the bacteria that cause the better known Lethal Yellowing disease that attacks palm species.

Ironically, PNG was selected as the site for the gene bank in the 1990s because the country was relatively free of coconut pests and diseases.

In an attempt to contain the disease, movement of coconuts and coconut palms, both from the gene bank and for commercial reasons, out of the affected region has been banned, with roadblocks in place to help enforce this.

But these restrictions are preventing the gene bank from fulfilling one of its key roles: distributing useful varieties in support of R&D efforts.

The gene bank holds 3,200 coconut palms, representing 57 different varieties of Cocos nucifera, and is one of five international coconut collections around the world.

Roland Bourdeix, coordinator of the International Coconut Genetic Resources Network, is arranging an urgent mission to PNG to assess the situation.

Read more from the original source:
South Pacific coconut gene bank under threat

Recommendation and review posted by Bethany Smith

ScienceDaily (Nov. 13, 2012) Why do we get older? When do we die and why? Is there a life without aging? For centuries, science has been fascinated by these questions. Now researchers from Kiel (Germany) have examined why the polyp Hydra is immortal -- and unexpectedly discovered a link to aging in humans.

The study carried out by Kiel University together with the University Medical Center Schleswig-Holstein (UKSH) will be published this week in the Proceedings of the National Academy of Sciences (PNAS).

Hydra -- mysteriously immortal

The tiny freshwater polyp Hydra does not show any signs of aging and is potentially immortal. There is a rather simple biological explanation for this: these animals exclusively reproduce by budding rather than by mating. A prerequisite for such vegetative-only reproduction is that each polyp contains stem cells capable of continuous proliferation. Without these stem cells, the animals could not reproduce any more. Due to its immortality, Hydra has been the subject of many studies regarding aging processes for several years.

Aging in humans

When people get older, more and more of their stem cells lose the ability to proliferate and thus to form new cells. aging tissue cannot regenerate any more, which is why for example muscles decline. Elderly people tend to feel weaker because their heart muscles are affected by this aging process as well. If it were possible to influence these aging processes, humans could feel physically better for much longer. Studying animal tissue such as those of Hydra -- an animal full of active stem cells during all its life -- may deliver valuable insight into stem cell aging as such.

Human longevity gene discovered in Hydra

"Surprisingly, our search for the gene that causes Hydra to be immortal led us to the so-called FoxO gene," says Anna-Marei Bhm, PhD student and first author of the study. The FoxO gene exists in all animals and humans and has been known for years. However, until now it was not known why human stem cells become fewer and inactive with increasing age, which biochemical mechanisms are involved and if FoxO played a role in aging. In order to find the gene, the research group isolated Hydra's stem cells and then screened all of their genes.

Immortality mechanism of Hydra revealed

The Kiel research team examined FoxO in several genetically modified polyps: Hydra with normal FoxO, with inactive FoxO and with enhanced FoxO. The scientists were able to show that animals without FoxO possess significantly fewer stem cells. Interestingly, the immune system in animals with inactive FoxO also changes drastically. "Drastic changes of the immune system similar to those observed in Hydra are also known from elderly humans," explains Philip Rosenstiel of the Institute of Clinical Molecular Biology at UKSH, whose research group contributed to the study.

See the original post:
Solving the mystery of aging: Longevity gene makes Hydra immortal and humans grow older

Recommendation and review posted by Bethany Smith

New Delhi, Nov. 12: Scientists have identified a novel candidate gene for diabetes that they say appears to put Indians at a higher risk of the disease than any of the 56 diabetes genes discovered earlier.

A consortium of Indian researchers announced today that the new gene also seems to establish a link between the brain and diabetes, hinting at previously unknown disease mechanisms that scientists hope will eventually lead to new treatment strategies.

The gene called TMEM163, identified by the Indian Diabetes Consortium, makes a protein that plays a role in the transfer of signals between brain cells. Most of the earlier diabetes genes influence either the behaviour of insulin-producing cells in the pancreas or mechanisms of insulin resistance.

"We now have a new hypothesis about diabetes," said Dwaipayan Bharadwaj, a scientist at the Institute of Genomics and Integrative Biology in New Delhi and a member of the consortium. "People with one version of this gene are at risk of developing defective insulin secretion ' we're now trying to validate this idea through laboratory and animal experiments."

Bharadwaj and his colleagues identified the gene through India's largest genome study for diabetes that looked for genetic differences between 6700 patients with diabetes and 5700 persons without the disease. Their findings are scheduled for publication in the international journal Diabetes.

The study has also found that 49 among the 56 genes previously reported as associated with diabetes in other populations ' mainly white Caucasians are also observed in the Indian population.

But TMEM163, among all the candidate genes, appears to confer the highest risk of diabetes ' a person with a disease-associated variant of TMEM163 has 1.56 times higher risk of diabetes than a person without this variant.

A gene called TCF7L2 has until now shown the strongest association ' people with one variant of this gene have 1.51-fold higher risk of diabetes than people without that variant.

A senior endocrinologist who's a member of the consortium said that the new candidate gene and all the other known genes for diabetes explain only about eight per cent of the extra risk of diabetes among Indians.

"Diet and lifestyle appear to contribute far more to the risk of diabetes than genes ' so diet and exercise still remain a key to diabetes control," said Nikhil Tandon, professor of endocrinology at the All India Institute of Medical Sciences in New Delhi. "But the new gene is interesting because it opens a new avenue for research to understand underlying mechanisms of the disease."

Excerpt from:
Scientists unravel new diabetes gene

Recommendation and review posted by Bethany Smith

MEMPHIS, Tenn., Nov. 12, 2012 /PRNewswire/ -- Research led by the St. Jude Children's Research Hospital Washington University Pediatric Cancer Genome Project has identified a fusion gene responsible for almost 30 percent of a rare subtype of childhood leukemia with an extremely poor prognosis.

To view the multimedia assets associated with this release, please click: http://www.multivu.com/mnr/58586-st-jude-children-s-research-hospital-gene-sequencing-childhood-leukemia

The finding offers the first evidence of a mistake that gives rise to a significant percentage of acute megakaryoblastic leukemia (AMKL) cases in children. AMKL accounts for about 10 percent of pediatric acute myeloid leukemia (AML). The discovery paves the way for desperately needed treatment advances.

Investigators traced the genetic misstep to the rearrangement of chromosome 16, which brings together pieces of two genes and sets the stage for production of an abnormal protein. The fusion protein features the front end of CBFA2T3, a blood protein, and the back of GLIS2, a protein that is normally produced only in the kidney. Work that appears in the November 13 edition of the journal Cancer Cell reports that in a variety of laboratory models the CBFA2T3-GLIS2 protein switched on genes that drive immature blood cells to keep dividing long after normal cells had died. This alteration directly contributes to leukemia.

AMKL patients with the fusion gene were also found to be at high risk of failing therapy. Researchers checked long-term survival of 40 AMKL patients treated at multiple medical centers around the world and found about 28 percent of patients with the fusion gene became long-term survivors, compared to 42 percent for patients without CBFA2T3-GLIS2. Overall long-term survival for pediatric AML patients in the U.S. is now 71 percent.

"The discovery of the CBFA2T3-GLIS2 fusion gene in a subset of patients with AMKL paves the way for improved diagnostic testing, better risk stratification to help guide treatment and more effective therapeutic interventions for this aggressive childhood cancer," said James Downing, M.D., St. Jude scientific director and the paper's corresponding author. The first author is Tanja Gruber, M.D., Ph.D., an assistant member in the St. Jude Department of Oncology.

Co-author Richard Wilson, Ph.D., director of The Genome Institute at Washington University School of Medicine in St. Louis, noted: "We identified this unusual gene fusion by comparing the genome of children's healthy cells with the genome of their cancer cells. This type of in-depth exploration and analysis is crucial to finding unexpected structural rearrangements in the DNA that can lead to cancer. With this discovery, we now can search for more effective treatment options that target this precise defect."

The study is part of the Pediatric Cancer Genome Project, a three-year collaboration between St. Jude and Washington University to sequence the complete normal and cancer genomes of 600 children and adolescents with some of the most aggressive and least understood cancers. The human genome is the instruction book for assembling and sustaining a person. The instructions are packaged in the DNA molecule. Sequencing the genome involves determining the exact order of the four chemical bases that make up DNA. Human DNA is organized into 46 chromosomes.

"We focused on AMKL because no one had any idea of what caused this leukemia in most patients," Gruber said. The study excluded AMKL patients who were infants or children with Down syndrome because earlier research had linked their disease to other chromosomal rearrangements.

When researchers in this study sequenced just the genes that were switched on in the AMKL cells of 14 young patients, the scientists discovered half carried the CBFA2T3-GLIS2 fusion. Additional fusion genes were identified in five of the other patients. Each of those fusion genes occurred in a single patient. The genes involved included HOXA9 and MN1, both previously linked to leukemia, and GATA2 and FLII, which play roles in normal development of the megakaryocytic blood cells that are targeted in AMKL. Megakaryocytes produce the platelets that help blood clot.

Read more:
Gene sequencing project identifies abnormal gene that launches rare childhood leukemia

Recommendation and review posted by Bethany Smith

Black Sheep Part 1 Full Movie
full movie : tinyurl.com Black Sheep Part 1 Full Movie, Black Sheep Part 1 Movie, Black Sheep Movie Part 1, Black Sheep Part 1 The Movie, Black Sheep Part 2 Full Movie, Black Sheep Movie Full Movie, Black Sheep (2006) Movie Part 1 English Full, Black Sheep Movie HD trailer. An experiment in genetic engineering turns harmless sheep into blood-thirsty killers that terrorize a sprawling New Zealand farm.From:talcean teriViews:0 0ratingsTime:06:10More inFilm Animation

Read more:
Black Sheep Part 1 Full Movie - Video

Recommendation and review posted by Bethany Smith

Millions Spent Defeating Prop 37-GMO #39;s: Why They Don #39;t Want Us To Know What We #39;re Eating
Howard Vlieger began studying GMO crops in 1994 and is fortunate to work with some of the lead scientists in the world on research projects involving GMO crops. The real life experience that he has from being a farmer and working with farmers all across the US gives him a unique perspective on GMOs. Howard has been giving presentations to educate people about GMOs for more than 6 years in 13 states. Howard serves on the board of directors for the Farm and Ranch Freedom Alliance (FARFA) and the Food Freedom Foundation. Show Highlights: Howard Vlieger and his organization Verity Farms have been researching the affects of genetically engineered crops on the soil, animals and humans since 1992. What they have learned and see every day in 2012 is beyond spooky. -The gut ecology is impaired when animals and humans consume GM organisms, at one tenth of a part per million -BT Corn linked to poor conception rates, immune and digestive issues -There are three top issues with genetic engineering of crops: the ecology of the soil, immune and digestive disruption and super weeds requiring more and more glyphosates. -The birds and the bees are affected -The story behind Roundup Ready Alfalfa, and it #39;s not pretty -These foreign proteins with GMO #39;s are not digestible. Period -Are you eating eggs fed GMO corn and Soy? -The Germans are saying No to GMO #39;s -A strong immune system and our own garden are our best defense here. -In 2010, 170 million acres of corn and soy were planted -- 92% GMO ...From:Patrick TimponeViews:1531 13ratingsTime:09:56More inScience Technology

Here is the original post:
Millions Spent Defeating Prop 37-GMO's: Why They Don't Want Us To Know What We're Eating - Video

Recommendation and review posted by Bethany Smith

DUBLIN--(BUSINESS WIRE)--

Research and Markets (http://www.researchandmarkets.com/research/vvb7t7/bioprocess) has announced the addition of Elsevier Science and Technology's new book "Bioprocess Engineering" to their offering.

Bioprocess Engineering involves the design and development of equipment and processes for the manufacturing of products such as food, feed, pharmaceuticals, nutraceuticals, chemicals, and polymers and paper from biological materials. It also deals with studying various biotechnological processes.

"Bioprocess Kinetics and Systems Engineering" first of its kind contains systematic and comprehensive content on bioprocess kinetics, bioprocess systems, sustainability and reaction engineering.

Dr. Shijie Liu reviews the relevant fundamentals of chemical kinetics-including batch and continuous reactors, biochemistry, microbiology, molecular biology, reaction engineering, and bioprocess systems engineering- introducing key principles that enable bioprocess engineers to engage in the analysis, optimization, design and consistent control over biological and chemical transformations.

The quantitative treatment of bioprocesses is the central theme of this book, while more advanced techniques and applications are covered with some depth. Many theoretical derivations and simplifications are used to demonstrate how empirical kinetic models are applicable to complicated bioprocess systems.

Key Features

- Contains extensive illustrative drawings which make the understanding of the subject easy

- Contains worked examples of the various process parameters, their significance and their specific practical use

- Provides the theory of bioprocess kinetics from simple concepts to complex metabolic pathways

Continue reading here:
Research and Markets: Bioprocess Engineering

Recommendation and review posted by Bethany Smith